trial · primary record
Busulfan
WHIM
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 10 |
| Primary completion | 2033-12-31 |
| Primary endpoint | To evaluate the safety of base-edited autologous CD34+ cells |
| Registry ID | NCT07775313 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:39.525Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07775313
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.